Quick Answer
Kiniksa Pharmaceuticals International, plc reported Net Income Loss of $59.01 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +236.6% in Net Income Loss from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$11.20 million | Q3 2017: -$16.03 million | Q1 2018: -$15.98 million | Q2 2018: -$20.26 million | Q3 2018: -$24.41 million | Q1 2019: -$65.82 million | Q2 2019: -$37.19 million | Q3 2019: -$27.06 million | Q1 2020: -$26.42 million | Q2 2020: -$37.47 million | Q3 2020: -$43.84 million | Q1 2021: -$49.48 million | Q2 2021: -$41.56 million | Q3 2021: -$30.54 million | Q1 2022: -$25.21 million | Q2 2022: -$19.98 million | Q3 2022: $224.09 million | Q1 2023: -$12.27 million | Q2 2023: $14.97 million | Q3 2023: -$13.86 million | Q1 2024: -$17.70 million | Q2 2024: -$3.91 million | Q3 2024: -$12.69 million | Q1 2025: $8.54 million | Q2 2025: $17.83 million | Q3 2025: $18.44 million.
- Over the full 9 years of available data (2017 to 2025), Kiniksa Pharmaceuticals International, plc's Net Income Loss has grown by 191.0%.
- Historical annual values: Fiscal year 2025: $59.01 million | Fiscal year 2024: -$43.19 million | Fiscal year 2023: $14.08 million | Fiscal year 2022: $183.36 million | Fiscal year 2021: -$157.92 million | Fiscal year 2020: -$161.38 million | Fiscal year 2019: -$161.87 million | Fiscal year 2018: -$103.23 million | Fiscal year 2017: -$64.87 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: